Zacks Research Brokers Lower Earnings Estimates for Biogen

Biogen Inc. (NASDAQ:BIIB) – Equities researchers at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for Biogen in a research report issued to clients and investors on Thursday, August 14th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings per share of $3.81 for the quarter, down from their previous forecast of $3.85. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Biogen’s Q4 2025 earnings at $3.68 EPS, Q1 2026 earnings at $3.45 EPS, Q2 2026 earnings at $3.77 EPS, Q3 2026 earnings at $3.65 EPS, Q4 2026 earnings at $3.91 EPS, FY2026 earnings at $14.79 EPS, Q1 2027 earnings at $3.40 EPS, Q2 2027 earnings at $3.92 EPS and FY2027 earnings at $15.70 EPS.

BIIB has been the subject of a number of other research reports. The Goldman Sachs Group reduced their price objective on Biogen from $219.00 to $197.00 and set a “buy” rating for the company in a research report on Wednesday, April 23rd. Morgan Stanley reduced their price objective on Biogen from $146.00 to $144.00 and set an “equal weight” rating for the company in a research report on Friday, August 1st. Piper Sandler reissued a “neutral” rating and set a $118.00 price objective (up previously from $115.00) on shares of Biogen in a research report on Thursday. Citigroup lifted their price objective on Biogen from $125.00 to $135.00 and gave the company a “neutral” rating in a research report on Friday, August 1st. Finally, Mizuho reduced their price objective on Biogen from $207.00 to $169.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. Twenty-one research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $185.74.

Biogen Stock Performance

Shares of Biogen stock opened at $138.60 on Monday. The stock has a market cap of $20.32 billion, a PE ratio of 13.25, a price-to-earnings-growth ratio of 1.09 and a beta of 0.13. Biogen has a 12 month low of $110.04 and a 12 month high of $207.59. The company has a quick ratio of 1.79, a current ratio of 2.50 and a debt-to-equity ratio of 0.36. The business has a fifty day simple moving average of $130.13 and a 200-day simple moving average of $130.84.

Biogen (NASDAQ:BIIB) last issued its earnings results on Thursday, July 31st. The biotechnology company reported $5.47 EPS for the quarter, topping the consensus estimate of $3.93 by $1.54. The business had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.32 billion. Biogen had a return on equity of 13.85% and a net margin of 15.31%. Biogen’s revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the firm posted $5.28 earnings per share.

Insider Activity at Biogen

In other news, insider Rachid Izzar sold 2,223 shares of Biogen stock in a transaction dated Tuesday, July 8th. The stock was sold at an average price of $135.00, for a total value of $300,105.00. Following the transaction, the insider directly owned 6,330 shares in the company, valued at approximately $854,550. The trade was a 25.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.18% of the company’s stock.

Hedge Funds Weigh In On Biogen

A number of institutional investors have recently made changes to their positions in BIIB. Elevation Point Wealth Partners LLC bought a new position in shares of Biogen in the second quarter worth about $25,000. Opal Wealth Advisors LLC bought a new position in shares of Biogen in the first quarter worth about $26,000. Vision Financial Markets LLC bought a new position in shares of Biogen in the first quarter worth about $27,000. Greykasell Wealth Strategies Inc. bought a new position in Biogen during the first quarter valued at about $27,000. Finally, Rothschild Investment LLC increased its stake in Biogen by 64.7% during the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 88 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.